Pembrolizumab (PD-1 Blocking Antibody)

DRUG2 trials

Conditions

Esophageal Squamous Cell CarcinomaHead and Neck CancerMalignant MelanomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeSmall Cell and Non-small Cell Lung CancerSolid TumorSquamous Cell Carcinoma of LarynxSquamous Cell Carcinoma of Nasopharynx

Phase 1

RAPA-201 Therapy of Solid Tumors

RecruitingNCT05144698

Rapa Therapeutics LLCEsophageal Squamous Cell Carcinoma, Head and Neck Cancer, Malignant Melanoma +6

Start: 2021-08-01End: 2026-12-31Target: 37Updated: 2025-05-14

Phase 2

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

NCT03107962

Mingzhi ZhangNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Start: 2017-02-19End: 2018-12-31Target: 20Updated: 2017-04-11

Journal for ImmunoTherapy of Cancer2025-01-011 citations

1028 Ex vivo chemotherapy resistance of metabolically reprogrammed autologous Th1/Tc1 cells (RAPA-201): Towards the clinical translation of immune-sparing host conditioning

Regular and Young Investigator Award Abstracts2023-10-31

723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

Regular and Young Investigator Award Abstracts2023-10-31

Pembrolizumab (PD-1 Blocking Antibody)

Sponsors

Conditions

Phase 1

Phase 2

Related Papers